TapImmune, Inc. TPIV Archives

MondayApr 19, 2010 12:14 pm

TapImmune, Inc. (TPIV.OB) Developing Therapeutic Cancer Vaccines

TapImmune Inc. is a biotechnology company known for innovative approach of fighting cancer and other diseases through the use of preventative and therapeutic vaccines. The company's program for a therapeutic vaccine to unspecific tumors represents a conceptual leap in the design of therapeutic cancer vaccines. In pre-clinical studies, TapImmune's AdhTAP vaccine has been shown to increase the sensitivity of the immune system to recognize and destroy cancerous cells. This result is achieved by resurrecting the expression of MHC class 1 restricted tumor antigens on the cell surface. The action of the immune system, specifically the killer T-cells, to recognize and…

MondayApr 12, 2010 11:47 am

TapImmune, Inc. (TPIV.OB) Closes In On Magic Bullet Technology

TapImmune Inc., a growing biotechnology company known for its innovative approach to fighting cancer and infectious diseases, is focused on a vaccine technology based on modulating the activity of the body’s own defense mechanisms to help it identify and fight off infected and/or cancerous cells. Although the idea of assisting the body’s immune system is not new, TapImmune’s achievements have been especially encouraging. The company’s developments have been written up in a number of prestigious scientific journals, and have even broken through to the popular press with television and magazine coverage. TapImmune’s primary product is the TAP vaccine, based on…

TuesdayApr 06, 2010 2:38 pm

TapImmune, Inc. (TPIV.OB) Sees a Large Market Opportunity for Its TAP Vaccine Technology

TapImmune Inc. is a biotech firm focused on increasing the efficacy of vaccines by enhancing antigen presentation through the use of the Transporter of Antigen Processing (TAP). The company's technology has broad applications in developing therapeutic and preventative vaccines. TapImmune's strategy is to build a patented proprietary product pipeline and capitalize on the breadth of the TAP technology through collaborative partnerships and license agreements. The global vaccine market is estimated to be a $21 billion market in 2010. TapImmune sees large market opportunities for their TAP vaccine technology in the areas of prevention and treatment of infectious diseases and cancer.…

WednesdayMar 31, 2010 1:44 pm

TapImmune, Inc. (TPIV.OB) Provides Shareholders with a Corporate Update

TapImmune Inc. is a company focused on increasing the efficacy of vaccines by enhancing antigen presentation through the use of the Transporter of Antigen Processing (TAP). Replacement of this transporter provides a significant immune response with the potential to treat a variety of cancers which lack normal amount of TAP. The company is working on several significant products. TapImmune's lead product candidate, AdhTAP, is designed to restore and augment antigen presentation and subsequent recognition and killing of cancer cells by the immune system. The company is scheduled to move ahead with clinical manufacturing and toxicology studies for this cancer therapy.…

WednesdayMar 24, 2010 11:50 am

TapImmune, Inc. (TPIV.OB) to Collaborate with Aeras Global to Develop Tuberculosis Vaccine

TapImmune Inc., biotech innovator and developer of therapies for infectious disease and oncology, and creator of the revolutionary TAP vaccine which has ability to restore antigen presentation in cells, announced in February of this year the signing of a letter of intent to begin a collaborative R&D campaign with Aeras Global TB Vaccine Foundation. Aeras is dedicated to moving leading tuberculosis vaccines forward and making worldwide distribution and adoption of them ubiquitous despite age group or income level. Aeras operates under private foundations like The Bill & Melinda Gates Foundation, and accepts governmental aid as a non-profit product development partnership.…

WednesdayMar 24, 2010 9:28 am

TapImmune, Inc. (TPIV.OB) Video Chart for Wednesday, March 24, 2010

TapImmune, Inc. is a low-float stock play that has a chart positioned to possibly reap some very nice gains. Technical analysis says to use support levels as entry points. Watch the video to see why TPIV is poised to move. To view the video, please click the following link: http://www.qualitystocks.net/videocharts.php?chartvid_id=360 Let us hear your thoughts: TapImmune, Inc. Message Board

TuesdayFeb 23, 2010 11:21 am

Beacon Equity Research Featured Company: TapImmune, Inc. (TPIV.OB)

TapImmune, Inc. is a biotechnology company focused on developing innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company’s lead product, the TAP vaccine, is a key component of a mechanism that moves characteristic markers called antigens to the surfaces of cells. Without TAP, there is a large reduction in presentation of cancer markers, making it impossible for the immune system to spot rogue cells and cancerous cells, allowing them to grow undetected. The company’s vaccine has demonstrated its effectiveness in restoring TAP which in-turn restores and augments the characteristic marker (antigen) and subsequent recognition and…

FridayDec 11, 2009 9:32 am

TapImmune, Inc. (TPIV.OB) ‘Tapping’ into Market for Therapeutic and Preventative Vaccines

TapImmune Inc. is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company's TAP (transporters associated with antigen processing) technology has been featured in media outlets such ABC News, Business Week and Popular Mechanics as well as in many respected medical journals such as the Journal of Immunology. The company's lead product, the TAP vaccine, performs a key step in moving characteristic markers called antigens to the surfaces of cells. Without TAP – there are no cancer markers – so the body's immune system fails to spot the…

TuesdayDec 08, 2009 4:20 pm

TapImmune, Inc. (TPIV.OB) – Magic Bullets

Every day, more than 20,000 people die from some form of cancer worldwide. In the U.S., it’s approximately 1,500 deaths from cancer every day (more than 10 times the number of people that die in automobile accidents). Cancer is the second leading cause of death in the U.S., next to heart disease, accounting for nearly a quarter of all recorded deaths. There are many types of cancer, with each kind being more or less deadly than others. But, overall, if you do get cancer, there’s nearly a 50% chance that it will eventually take your life. The unique nature of…

WednesdayDec 02, 2009 11:40 am

TapImmune, Inc. (TPIV.OB) Signs License Agreement with Crucell (CRXL)

TapImmune Inc., best known for developing immunotherapeutic vaccines for cancer and infectious diseases, announced recently that it has signed a license agreement with Crucell N.V. (NASDAQ: CRXL), a global biopharmaceutical company based in the Netherlands. The license allows TapImmune to use Crucell’s proprietary PER.C6® cells in its development programs. The cell line is ideal for the development and large-scale production of a wide variety of biopharmaceuticals. Specifically, PER.C6 cells do not generate replication competent adenoviruses in the use of recombinant vaccines using adenoviral vectors, making it excellent for the production of adenoviral vectors for clinical applications. Generally, the PER.C6 cell…

Site Search

Company Search

Tag: TapImmune, Inc. TPIV